New biotech Naia gets exclusive global license to two Amunix compounds
Amunix Operating Inc. licensed newly created Naia Ltd. exclusive global rights to its Phase I glucagon-like peptide-1 (GLP-1) receptor agonist GLP-1-XTEN (renamed NB1001) for Type II diabetes, and preclinical GLP-2-XTEN (NB1002), a GLP-2 receptor agonist for short bowel syndrome.
- Large Molecule
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.